| |
Tuesday, October 11, 2022 | 10am ET / 7am PT Join us to learn about common pitfalls for rAAV processing and ways to overcome the challenges. Key for a successful process are high viral genome productivity and full capsids in the harvest material, with high overall yield and efficient impurity removal. Register now. 
|
|
Today's Big NewsOct 3, 2022 |
Spying a devilish deal, AstraZeneca pays 666% premium to buy genomic medicine biotech Clene break: Biotech’s shares slump 30% on ALS phase 2 flop Incyte scoops up preclinical biotech to widen footprint in vitiligo SPAC on track: Preclinical T-cell company Estrella latest in string of biotechs to take blank check route After $100M deal, J&J links gene therapy to improved vision in early-phase trial Mesoblast keeps hopes of cell therapy approval alive in latest response to FDA Fierce Biotech Summit: Gene editing execs reflect on promises and challenges as CRISPR celebrates 10-year anniversary Scandion posts phase 2 trial flop just one month after the departure of 2 top execs Don't junk DNA as study shows new role in brain disease |
| By Nick Paul Taylor AstraZeneca has identified a shortcut to prominence in the genomic medicine space. Working through its Alexion rare disease unit, the Big Pharma has struck a deal to snap up struggling LogicBio Therapeutics to secure technology platforms and expertise in their use. |
|
|
|
By James Waldron Clene Nanomedicine came up short in a phase 2 trial of its only clinical-stage asset in amyotrophic lateral sclerosis but is nonetheless laying a path forward for the drug in ALS. As a result, the biotech’s shares plummeted 34% from $2.80 apiece on Friday to $1.83 as the markets opened Monday. |
By Max Bayer Incyte is scooping up a preclinical biotech to potentially expand its vitiligo treatment footprint. The company is shelling out $70 million upfront to buy Villaris Therapeutics, with more than $1.36 billion available in biobucks. |
By Gabrielle Masson A string of recent biotech SPAC mergers in biotech could put the so-called blank check deals back on track after near-extinction. The latest is early-stage cancer therapeutics company Estrella Biopharma, which signed a deal to merge with TradeUP Acquisition. Corp. |
By Nick Paul Taylor Johnson & Johnson has posted clinical data on its $100 million gene therapy bet. The Big Pharma linked its inherited retinal disease candidate to improved vision in a phase 1/2 clinical trial, offering insights into how it may perform in an ongoing pivotal study. |
By James Waldron Mesoblast isn’t giving up on its allogeneic cell therapy remestemcel-L. The FDA knocked back the biotech in September 2020, issuing a complete response letter to Mesoblast’s approval request for its mesenchymal stromal cell therapy in children with steroid-resistant graft-versus-host disease. |
By Angus Liu The first wave of gene-editing-based therapies are coming to fruition. At the recent Fierce BIotech Summit, executives from Beam, Intellia, Novartis and Tessera highlighted progresses in the burgeoning field in the past ten years as well as challenges before gene editing could reach more patients. |
By Max Bayer Just a month after two top executives announced their departure, Scandion posted a phase 2 flop of its sole asset. The company says SCO-101 failed to produce a high enough tumor reduction rate to pass the trial's primary endpoint. |
By Helen Floersh Researchers at the University of Sheffield have discovered that junk DNA, or non-coding DNA, can break—and if it isn’t repaired, can contribute to the development of neurodegenerative disease. They hope their findings will lead to the identification of disease biomarkers along with new therapies. |
By Conor Hale Catapult will propel the Tasso+ blood collector into people's homes as part of its VirtualCheckup program. |
By Fraiser Kansteiner Late last week, Otsuka’s Taiho Oncology and Taiho Pharmaceutical nabbed accelerated approval for their drug futibatinib in adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma in the liver with fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements. |
By Dave Muoio A new analysis estimates 25 coastal metros would see the majority of their hospitals hamstrung by a Category 2 hurricane or stronger. The number is only expected to increase as climate change raises sea levels. |
By Conor Hale Researchers at the university have developed a motorized pill with a spinning, augerlike end piece designed to displace the mucus and deliver its payload directly to the organ. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market. |
|
|---|
|
|
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT Data |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
